Fresh Data Backs Amplia Push Against Pancreatic, Ovarian Cancer Recent research at Australia's Garvan Institute of Medical Research has brought new hope to patients and families affected by pancreatic cancer.
The study, led by Professor Paul Timpson with assistance from Amplia Therapeutics, focuses on a promising therapy called narmafotinib.
Narmafotinib targets focal adhesion kinase (FAK), a protein that plays a crucial role in cancer cell movement, survival, and attachment.